Atherosclerotic Risk Factors, Prevention, and Medical Optimization
Medical optimization in vascular surgery begins by placing the patient in the correct prevention frame: asymptomatic primary prevention, established PAD, or a perioperative vascular pathway. From that frame, the clinician builds a practical plan for lipid lowering, blood-pressure control, diabetes therapy, antithrombotic selection, smoking cessation, structured exercise, and residual-risk monitoring tailored to the specific clinical context.
Choose a chapter overview or a specialist discussion. Each recording follows this published edition.
General medical education, not patient-specific advice.
Risk stratification and prevention sequencing
Medical optimization applies different therapeutic intensities depending on whether the patient is in primary prevention, established peripheral arterial disease () secondary prevention, or a perioperative pathway. For patients without established vascular disease, cardiovascular risk is estimated using primary-prevention calculators such as SCORE2, the PREVENT equations, and pooled-cohort equations . This baseline risk estimate guides the allocation of lifestyle interventions and moderate-intensity pharmacotherapy.
Established symptomatic PAD, including , chronic limb-threatening ischemia, and prior limb revascularization, constitutes established atherosclerotic disease. Primary-prevention calculators underestimate risk in this population and do not justify de-escalating therapy . The perioperative pathway builds upon this prevention framework, shifting the immediate focus toward hemodynamic stability, renal protection, and bleeding risk prior to intervention, while long-term risk-factor modification is escalated during stable outpatient phases .
Primary prevention
- Primary focus
- Baseline cardiovascular risk estimation using validated calculators
- Modifying factors
- Age, sex, diabetes, kidney disease, and family history
CitationEstablished PAD
- Primary focus
- Secondary prevention with high-intensity risk modification
- Modifying factors
- Symptom severity, prior revascularization, and competing limb risk
CitationPerioperative pathway
- Primary focus
- Short-term procedural safety and medication reconciliation
- Modifying factors
- Bleeding risk, hemodynamic stability, and renal function
Citation
Secondary-prevention sequence
- Confirm established atherosclerotic disease and quantify cardiovascular risk.
- Start a high-intensity statin to the target, escalating to ezetimibe then a inhibitor.
- Lower blood pressure to below 130/80 mmHg when tolerated.
- Add glucose-lowering therapy with cardiovascular benefit (an inhibitor or receptor agonist) in high-risk diabetes.
- Set antithrombotic therapy: single antiplatelet baseline, adding dual-pathway rivaroxaban plus aspirin when bleeding risk is acceptable.
- Prescribe structured exercise and smoking cessation.
Lipid, blood-pressure, and cardiometabolic therapy
Lipid management follows a stepwise escalation based on clinical risk. A high-intensity statin is first-line, targeting at least a 50% reduction in low-density lipoprotein cholesterol () for established atherosclerotic disease (ACC/AHA), or an absolute target below 55 mg/dL alongside a 50% reduction in very-high-risk populations (ESC) . High-intensity means atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg daily, the doses that lower LDL-C by at least 50%; moderate-intensity regimens lower it roughly 30 to 49%. When patients remain above target on maximally tolerated statin therapy, ezetimibe is the first non-statin addition. In IMPROVE-IT, adding ezetimibe to statin therapy reduced cardiovascular events in high-risk patients . PCSK9 inhibitors are added for selected patients with persistent high residual risk; FOURIER (evolocumab) and ODYSSEY OUTCOMES (alirocumab) demonstrated further event reduction when added to background therapy in established cardiovascular disease . In primary prevention, JUPITER demonstrated that rosuvastatin reduces vascular events in patients selected for elevated inflammatory risk () despite baseline LDL-C values that do not typically trigger treatment .
Blood-pressure targets are tailored to the patient phenotype. The standard target is below 130/80 mmHg when tolerated . SPRINT demonstrated benefit from intensive systolic lowering in selected high-risk non-diabetic adults, while ACCORD BP failed to reproduce this overall cardiovascular benefit in patients with type 2 diabetes . Combined statin and blood-pressure lowering reduces events even in intermediate-risk global prevention (HOPE-3) . Therapy intensity is modified for frailty, orthostatic symptoms, kidney function, and the timing of vascular intervention.
Diabetes management integrates cardiovascular and renal protection beyond glycemic control. In patients with type 2 diabetes and high cardiovascular risk, SGLT2 inhibitors and GLP-1 receptor agonists are prioritized. EMPA-REG OUTCOME (empagliflozin) and DECLARE-TIMI 58 (dapagliflozin) established the outcome evidence for SGLT2 inhibitors, while LEADER (liraglutide) and SUSTAIN-6 (semaglutide) established benefits for GLP-1 receptor agonists in high-risk populations .
- Lipids
- Target or regimen
- >= 50% LDL-C reduction (ACC/AHA) or < 55 mg/dL (ESC)
- Escalation pathway
- High-intensity statin, then ezetimibe, then PCSK9 inhibitor
Citation - Blood pressure
- Target or regimen
- < 130/80 mmHg when tolerated
- Escalation pathway
- Adjust for frailty, falls, and renal function
Citation - Diabetes
- Target or regimen
- Individualized target
- Escalation pathway
- SGLT2 inhibitors or GLP-1 receptor agonists in high-risk groups
Citation
Antithrombotic selection
Antithrombotic therapy in vascular patients separates into three distinct indications: primary prevention, stable atherosclerotic disease, and post-revascularization. For primary prevention, the ASPREE, ASCEND, and ARRIVE trials demonstrated that the modest vascular benefit of aspirin is offset by bleeding risk. Routine initiation of aspirin for primary prevention is not recommended for most adults .
For stable PAD, single antiplatelet therapy (aspirin or clopidogrel) is the Class 1 baseline for symptomatic disease . Standard doses are aspirin 75 to 100 mg daily (81 mg in US practice) or clopidogrel 75 mg daily. The aspirin partner in both COMPASS and VOYAGER dual-pathway regimens is aspirin 100 mg daily . Dual-pathway inhibition intensifies this baseline in patients with acceptable bleeding risk: COMPASS demonstrated that adding very-low-dose rivaroxaban (2.5 mg twice daily) to aspirin reduces major cardiovascular and limb events compared to aspirin alone, at the cost of increased major bleeding .
After lower-extremity revascularization, VOYAGER PAD tested rivaroxaban 2.5 mg twice daily versus placebo on an aspirin background and reduced a composite of acute limb ischemia, major vascular amputation, myocardial infarction, ischemic stroke, or cardiovascular death. Clopidogrel was permitted; this was not a direct comparison with DAPT, and a composite benefit does not establish significant benefit for every component . Antithrombotic decisions require an assessment of bleeding risk, prior intervention, coronary overlap, and concomitant therapeutic anticoagulation .
- Primary prevention
- Preferred regimen
- Avoid routine aspirin
- Key caveats
- Benefit limited by bleeding risk in patients without established disease
Citation - Stable PAD (Class 1 baseline)
- Preferred regimen
- Single antiplatelet therapy (aspirin or clopidogrel)
- Key caveats
- First-line for symptomatic disease; continue indefinitely unless contraindicated
Citation - Stable PAD (dual-pathway intensification)
- Preferred regimen
- Add rivaroxaban 2.5 mg twice daily to aspirin
- Key caveats
- Reserved for patients with acceptable bleeding risk to further reduce major cardiovascular and limb events; assess fall risk and concomitant anticoagulation
Citation - Post-revascularization
- Preferred regimen
- Antiplatelet therapy; consider the applicable dual-pathway or time-limited DAPT strategy below
- Key caveats
- Select by procedure, graft material, bleeding risk, and any separate anticoagulation indication; do not combine regimens automatically
Citation
Lifestyle modification and residual risk
Smoking cessation and structured exercise are primary therapeutic interventions for PAD. Continued smoking after revascularization accelerates restenosis, progression, and wound complications. Pharmacologic cessation support combined with structured counseling is superior to clinical advice alone .
For chronic symptomatic PAD, supervised exercise or a structured community-based program, including home-based exercise with behavioral support, can improve walking ability, function and quality of life. Either structured approach can be offered initially for functionally limiting claudication; simple advice to walk is not equivalent to a structured program . PAD carries high systemic risk, including renal functional decline, making integrated management of exercise, blood pressure, and renal surveillance necessary . Revascularization is reserved for selected patients with lifestyle-limiting symptoms, anatomic indications, or chronic limb-threatening ischemia, and does not replace walking therapy for claudication.
Residual risk persists despite conventional risk-factor control. Elevated lipoprotein(a), adverse body-fat distribution, and inflammatory markers such as interleukin-6 are associated with elevated atherosclerotic event rates . These biomarkers identify patients who benefit from aggressive secondary prevention and specialist input .
Areas of controversy
Risk prediction models developed for primary prevention frequently under-predict territory-specific limb risk in patients with established PAD, creating tension regarding when to escalate therapy beyond standard calculator thresholds. The direct translation of cardiovascular event reductions from coronary-anchored lipid trials into PAD-specific limb outcomes also remains debated due to outcome heterogeneity across studies. Finally, the use of biomarkers such as lipoprotein(a) and hs-CRP as independent triggers for targeted pharmacotherapy, rather than broad risk modifiers, continues to evolve as trial evidence matures.
Antithrombotic therapy after PAD revascularization. Uncertainty concerns selection and duration, not equivalence of all regimens. Regimen choice requires assessment of bleeding risk and contraindications; the rivaroxaban-plus-aspirin strategy is for eligible patients without increased bleeding risk. ACC/AHA 2024 distinguishes:
| Situation | Recommendation |
|---|---|
| Endovascular or surgical revascularization | Low-dose rivaroxaban 2.5 mg twice daily plus low-dose aspirin is recommended to reduce cardiovascular and limb events (1, A). |
| Endovascular revascularization | DAPT with a P2Y12 inhibitor plus low-dose aspirin is reasonable for 1–6 months (2a, C-LD). |
| Prosthetic surgical graft | DAPT may be reasonable for at least one month (2b, B-R). |
| Full-intensity anticoagulation required for another indication | Adding one antiplatelet is reasonable after revascularization when bleeding risk is not high (2a, C-LD). |
| No separate anticoagulation indication | Full-intensity oral anticoagulation should not be used solely to prevent PAD cardiovascular/limb events (3: Harm, A). |
- Recommendation
- Low-dose rivaroxaban 2.5 mg twice daily plus low-dose aspirin is recommended to reduce cardiovascular and limb events (1, A).
- Recommendation
- DAPT with a P2Y12 inhibitor plus low-dose aspirin is reasonable for 1–6 months (2a, C-LD).
- Recommendation
- DAPT may be reasonable for at least one month (2b, B-R).
- Recommendation
- Adding one antiplatelet is reasonable after revascularization when bleeding risk is not high (2a, C-LD).
- Recommendation
- Full-intensity oral anticoagulation should not be used solely to prevent PAD cardiovascular/limb events (3: Harm, A).
The rivaroxaban vascular dose is not a substitute for therapeutic anticoagulation for atrial fibrillation or VTE . CASPAR was neutral overall after below-knee bypass, with a favorable prespecified prosthetic-graft subgroup but not a vein-graft benefit. Its findings do not prove that DAPT is superior or equivalent to dual-pathway inhibition .
Further reading
- PCSK9 inhibitors and ezetimibe with or without statin therapy for cardiovascular risk reduction: a systematic review and network meta-analysis. (2022). Lipid-lowering treatments and cardiovascular risk; network comparisons require indirectness caveats.
References
- 1.SCORE2 risk prediction algorithms for Europe. 2021.PubMed-indexed article2021
SCORE2 risk prediction algorithms for Europe. 2021. PMID:34120177.
- 2.Comparison of pooled cohort equation and PREVENT™ risk calculator for statin treatment allocation. Atherosclerosis. 2024.PubMed-indexed article2024
Comparison of pooled cohort equation and PREVENT™ risk calculator for statin treatment allocation. Atherosclerosis. 2024. doi:10.1016/j.atherosclerosis.2024.118626.
- 3.Validation of the Framingham General Cardiovascular Risk Score and Pooled Cohort Equations in a Community-Based Population: A Prospective Cohort Study Analysis 2006-2017. Acta Cardiologica Sinica. 2023.PubMed-indexed articleRegistry / cohort2023
Validation of the Framingham General Cardiovascular Risk Score and Pooled Cohort Equations in a Community-Based Population: A Prospective Cohort Study Analysis 2006-2017. Acta Cardiologica Sinica. 2023. doi:10.6515/acs.202311_39(6).20230405a.
- 4.AHA PREVENT Equations and Lipoprotein(a) for Cardiovascular Disease Risk : Insights From MESA and the UK Biobank. JAMA cardiology. 2025.PubMed-indexed articleRegistry / cohort2025
AHA PREVENT Equations and Lipoprotein(a) for Cardiovascular Disease Risk : Insights From MESA and the UK Biobank. JAMA cardiology. 2025. doi:10.1001/jamacardio.2025.1603.
- 5.2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 2019.PubMed-indexed articleClinical practice guideline2019
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 2019. doi:10.1161/cir.0000000000000678.
- 6.
- 7.2024 ACC/AHA multisociety guideline for lower extremity PAD (Circulation). 2024.DOI publisher routeClinical practice guideline2024
2024 ACC/AHA multisociety guideline for lower extremity PAD (Circulation). 2024. doi:10.1161/cir.0000000000001251.
- 8.
- 9.2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 2019.PubMed-indexed articleClinical practice guideline2018
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 2019. doi:10.1161/cir.0000000000000625.
- 10.
- 11.
- 12.Impact of Lipid-Lowering Combination Therapy With Statins and Ezetimibe vs Statin Monotherapy on the Reduction of Cardiovascular Outcomes: A Meta-analysis. Mayo Clinic proceedings. 2025.PubMed-indexed articleMeta-analysis / systematic review2025
Impact of Lipid-Lowering Combination Therapy With Statins and Ezetimibe vs Statin Monotherapy on the Reduction of Cardiovascular Outcomes: A Meta-analysis. Mayo Clinic proceedings. 2025. doi:10.1016/j.mayocp.2025.01.018.
- 13.Alternative LDL Cholesterol-Lowering Strategy vs High-Intensity Statins in Atherosclerotic Cardiovascular Disease: A Systematic Review and Individual Patient Data Meta-Analysis. JAMA cardiology. 2025.PubMed-indexed articleMeta-analysis / systematic review2025
Alternative LDL Cholesterol-Lowering Strategy vs High-Intensity Statins in Atherosclerotic Cardiovascular Disease: A Systematic Review and Individual Patient Data Meta-Analysis. JAMA cardiology. 2025. doi:10.1001/jamacardio.2024.3911.
- 14.
- 15.
- 16.PCSK9 inhibitors and ezetimibe with or without statin therapy for cardiovascular risk reduction: a systematic review and network meta-analysis. BMJ (Clinical research ed.). 2022.PubMed-indexed articleMeta-analysis / systematic review2022
PCSK9 inhibitors and ezetimibe with or without statin therapy for cardiovascular risk reduction: a systematic review and network meta-analysis. BMJ (Clinical research ed.). 2022. doi:10.1136/bmj-2021-069116.
- 17.
- 18.2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 2018.PubMed-indexed articleClinical practice guideline2017
2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 2018. doi:10.1161/hyp.0000000000000065.
- 19.2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension. 2023.PubMed-indexed articleClinical practice guideline2023
2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension. 2023. doi:10.1097/hjh.0000000000003480.
- 20.
- 21.
- 22.Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease.PubMed-indexed articleRandomized controlled trial2016
Yusuf S, Lonn E, Pais P, Bosch J, López-Jaramillo P, Zhu J, et al. Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease. N Engl J Med. 2016;374(21):2032-2043. doi:10.1056/nejmoa1600177. PMID:27039945.
- 23.
- 24.
- 25.
- 26.
- 27.
- 28.
- 29.Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial.PubMed-indexed articleRandomized controlled trial2018
Gaziano JM, Brotons C, Coppolecchia R, Cricelli C, Darius H, Gorelick PB, et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet. 2018;392(10152):1036-1046. doi:10.1016/S0140-6736(18)31924-X. PMID:30158069.
- 30.
- 31.2024 ACC/AHA multisociety guideline for lower extremity PAD (JACC version). 2024.PubMed CentralClinical practice guideline2024
- 32.
- 33.Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. 2018.PubMed-indexed articleRandomized controlled trial2018
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. 2018. doi:10.1016/s0140-6736(17)32409-1.
- 34.VOYAGER PAD rivaroxaban after lower-extremity revascularization.No stable evidence linkRandomized controlled trial2020
- 35.Cardiovascular and metabolic changes following 12 weeks of tobacco and nicotine pouch cessation: a Swedish cohort study. Harm reduction journal. 2025.PubMed-indexed articleRegistry / cohort2025
Cardiovascular and metabolic changes following 12 weeks of tobacco and nicotine pouch cessation: a Swedish cohort study. Harm reduction journal. 2025. doi:10.1186/s12954-025-01195-y.
- 36.Xu Z, Chuo J, Zhao X. Effectiveness of home-based walking exercise for patients with peripheral artery disease and intermittent claudication: a systematic review and meta-analysis. BMJ Open. 2025;15:e086013. Corrected 21 December 2025; correction PMID 41423301.PubMed-indexed articleMeta-analysis / systematic review2025
Xu Z, Chuo J, Zhao X. Effectiveness of home-based walking exercise for patients with peripheral artery disease and intermittent claudication: a systematic review and meta-analysis. BMJ Open. 2025;15:e086013. doi:10.1136/bmjopen-2024-086013. Corrected 21 December 2025; correction doi:10.1136/bmjopen-2024-086013corr1, PMID 41423301.
- 37.Peripheral artery disease and risk of kidney outcomes: The Atherosclerosis Risk in Communities (ARIC) study. Atherosclerosis. 2024.PubMed-indexed articleRegistry / cohort2024
Peripheral artery disease and risk of kidney outcomes: The Atherosclerosis Risk in Communities (ARIC) study. Atherosclerosis. 2024. doi:10.1016/j.atherosclerosis.2024.118558.
- 38.Association of Lipoprotein(a) and Interleukin-6 With Cardiovascular Risk: MESA and UK Biobank. Journal of the American College of Cardiology. 2025.PubMed-indexed articleRegistry / cohort2025
Association of Lipoprotein(a) and Interleukin-6 With Cardiovascular Risk: MESA and UK Biobank. Journal of the American College of Cardiology. 2025. doi:10.1016/j.jacc.2025.08.101.
- 39.Association of lipoprotein(a) and diabetes in primary prevention of coronary heart disease: The Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis. 2025.PubMed-indexed articleRegistry / cohort2025
Association of lipoprotein(a) and diabetes in primary prevention of coronary heart disease: The Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis. 2025. doi:10.1016/j.atherosclerosis.2025.119179.
- 40.Waist to hip ratio modifies the cardiovascular risk of lipoprotein (a): Insights from MESA. Progress in cardiovascular diseases. 2025.PubMed-indexed articleRegistry / cohort2025
Waist to hip ratio modifies the cardiovascular risk of lipoprotein (a): Insights from MESA. Progress in cardiovascular diseases. 2025. doi:10.1016/j.pcad.2025.03.001.
- 41.Editor's Choice – European Society for Vascular Surgery (ESVS) 2024 Clinical Practice Guidelines on the Management of Asymptomatic Lower Limb Peripheral Arterial Disease and Intermittent Claudication 2024-01.PubMed-indexed article2024
Editor's Choice – European Society for Vascular Surgery (ESVS) 2024 Clinical Practice Guidelines on the Management of Asymptomatic Lower Limb Peripheral Arterial Disease and Intermittent Claudication 2024-01. doi:10.1016/j.ejvs.2023.08.067.
- 42.Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial 2010-10.PubMed-indexed article2010
Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial 2010-10. doi:10.1016/j.jvs.2010.04.027.
Educational use only
AI assists this editorial workflow. Published updates are human-reviewed before publication.
Not intended to diagnose, monitor, predict, prognose, treat, or alleviate disease.
Verify clinically relevant information against primary sources and current guidelines.